This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Entrectinib may be an effective therapy for patients with NTRK fusion–positive solid tumors, regardless of tumor type. In a combined analysis of phase I and phase II trials, more than half of patients responded to the drug, with a similar response rate in patients whose cancer had spread to the brain.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't.
January 2019
Volume 9, Issue 1
Volume 9, Issue 1
Entrectinib Effective across NTRK Fusion–Positive Cancers
Jump to section
Advertisement